PMID- 32320527
OWN - NLM
STAT- MEDLINE
DCOM- 20201118
LR  - 20230202
IS  - 1934-6638 (Electronic)
IS  - 1934-662X (Linking)
VI  - 128
IP  - 8
DP  - 2020 Aug
TI  - Identification of circulating tumor cells using 4-color fluorescence in situ 
      hybridization: Validation of a noninvasive aid for ruling out lung cancer in 
      patients with low-dose computed tomography-detected lung nodules.
PG  - 553-562
LID - 10.1002/cncy.22278 [doi]
AB  - BACKGROUND: Approximately one third of needle biopsies that are performed to rule 
      out malignancy of indeterminate pulmonary nodules detected radiologically during 
      lung cancer screening are negative, thus exposing cancer-free patients to risks 
      of pneumothorax, bleeding, and infection. A noninvasive confirmatory tool (eg, 
      liquid biopsy) is urgently needed in the lung cancer diagnosis setting to 
      stratify patients who should receive biopsy versus those who should be monitored. 
      METHODS: A novel antigen-independent, 4-color fluorescence in situ hybridization 
      (FISH)-based method was developed to detect circulating tumor cells (CTCs) with 
      abnormalities in gene copy numbers in mononuclear cell-enriched peripheral blood 
      samples from patients with (n = 107) and without (n = 100) lung cancer. RESULTS: 
      Identification of CTCs using FISH probes at 10q22.3/CEP10 and 3p22.1/3q29 
      detected lung cancer cases with 94.2% accuracy, 89% sensitivity, and 100% 
      specificity compared with biopsy. CONCLUSION: The high accuracy of this liquid 
      biopsy method suggests that it may be used as a noninvasive decision tool to 
      reduce the frequency of unnecessary needle biopsy in patients with benign 
      pulmonary lesions.
CI  - (c) 2020 American Cancer Society.
FAU - Katz, Ruth L
AU  - Katz RL
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Zaidi, Tanweer M
AU  - Zaidi TM
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Pujara, Deep
AU  - Pujara D
AD  - Department of Neurology, McGovern Medical School at The University of Texas 
      Health Science Center at Houston, Houston, Texas.
FAU - Shanbhag, Namita D
AU  - Shanbhag ND
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Truong, Duy
AU  - Truong D
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Patil, Shekhar
AU  - Patil S
AD  - Department of Internal Medicine, McGovern Medical School at The University of 
      Texas Health Science Center at Houston, Houston, Texas.
FAU - Mehran, Reza J
AU  - Mehran RJ
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
AD  - Department of Thoracic and Cardiovascular Surgery, The University of Texas MD 
      Anderson Cancer Center, Houston, Texas.
FAU - El-Zein, Randa A
AU  - El-Zein RA
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
AD  - Department of Radiology, Houston Methodist Research Institute, Houston, Texas.
FAU - Shete, Sanjay S
AU  - Shete SS
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
AD  - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Kuban, Joshua D
AU  - Kuban JD
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
AD  - Department of Interventional Radiology, The University of Texas MD Anderson 
      Cancer Center, Houston, Texas.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20200422
PL  - United States
TA  - Cancer Cytopathol
JT  - Cancer cytopathology
JID - 101499453
SB  - IM
CIN - Cancer Cytopathol. 2020 Aug;128(8):518-519. PMID: 32320525
MH  - A549 Cells
MH  - Aged
MH  - Aneuploidy
MH  - Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Liquid Biopsy
MH  - Lung Diseases/*diagnosis/diagnostic imaging/genetics
MH  - Lung Neoplasms/*diagnosis/diagnostic imaging/genetics
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - *Neoplastic Cells, Circulating
MH  - Sensitivity and Specificity
MH  - Tomography, X-Ray Computed/*methods
OTO - NOTNLM
OT  - CTC
OT  - FISH
OT  - LDCT screening
OT  - indeterminate lung nodules
OT  - lung cancer
EDAT- 2020/04/23 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/04/23 06:00
PHST- 2019/10/28 00:00 [received]
PHST- 2020/01/09 00:00 [revised]
PHST- 2020/02/10 00:00 [accepted]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
PHST- 2020/04/23 06:00 [entrez]
AID - 10.1002/cncy.22278 [doi]
PST - ppublish
SO  - Cancer Cytopathol. 2020 Aug;128(8):553-562. doi: 10.1002/cncy.22278. Epub 2020 
      Apr 22.